Novel Molecular Therapeutics in Parkinson's Disease
- 16 February 2012
- book chapter
- Published by Wiley
- p. 245-265
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trialThe Lancet Neurology, 2010
- Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation updateHuman Mutation, 2010
- Functional enhancement and protection of dopaminergic terminals by RAB3B overexpressionProceedings of the National Academy of Sciences, 2009
- CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicityProceedings of the National Academy of Sciences, 2009
- Pink1 Forms a Multiprotein Complex with Miro and Milton, Linking Pink1 Function to Mitochondrial TraffickingBiochemistry, 2009
- Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous SystemJournal of Biological Chemistry, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- The E163K DJ-1 mutant shows specific antioxidant deficiencyBrain Research, 2008
- Heat Shock Transcription Factor 1-activating Compounds Suppress Polyglutamine-induced Neurodegeneration through Induction of Multiple Molecular ChaperonesJournal of Biological Chemistry, 2008
- Targeted delivery of proteins across the blood–brain barrierProceedings of the National Academy of Sciences, 2007